SCHEMBL4548405

SCHEMBL4548405

CCOC(=O)C(C)(Cc1cnc(Br)s1)C(=O)OCC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.43
MMP8 P22894 2/20 0.41
ALDH1A1 P00352 4/20 0.35
TSHR P16473 2/20 0.35
CYP1A2 P05177 2/20 0.35
ABCB11 O95342 1/20 0.35
CYP3A4 P08684 1/20 0.35
HTR2A P28223 1/20 0.35
PMP22 Q01453 1/20 0.35
PPARA Q07869 1/20 0.35
CNR2 P34972 2/20 0.35
CDC7 O00311 1/20 0.35
DBF4 Q9UBU7 1/20 0.35
HPGD P15428 2/20 0.33
CDK1 P06493 1/20 0.33
CDK4 P11802 1/20 0.33
CCNE1 P24864 1/20 0.33
CDK2 P24941 1/20 0.33
PIN1 Q13526 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4548402 0.80 PDK1 (0.33) SMN1; SMN2PPARACCNE1CDK2RECQL
SCHEMBL7453226 0.78 SMN1; SMN2 (0.69) SMN1; SMN2ALDH1A1TSHRCDK1CDK4
SCHEMBL1567646 0.75 SMN1; SMN2 (0.50) SMN1; SMN2ALDH1A1TSHRCYP1A2CYP3A4
SCHEMBL10246306 0.74 LMNA (0.31) LMNA
SCHEMBL17709819 0.72 SMN1; SMN2 (0.36) SMN1; SMN2MMP8TSHRCYP1A2ABCB11
SCHEMBL274346 0.70 CDC7 (0.59) SMN1; SMN2ALDH1A1TSHRCYP1A2CDC7
SCHEMBL16994851 0.70 HSD17B10 (0.49) SMN1; SMN2MMP8ALDH1A1TSHRHPGD
SCHEMBL7362869 0.69 MMP8 (0.59) SMN1; SMN2MMP8ALDH1A1TSHRCYP1A2
Hydrochloric Acid SCHEMBL1519816 0.69 CDC7 (0.57) SMN1; SMN2ALDH1A1CYP1A2CDC7DBF4
SCHEMBL24184211 0.69 CNR2 (0.38) SMN1; SMN2MMP8ALDH1A1TSHRCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178750-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. (US) 2012-07-12 US disclosed
US-20120178750-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. (US) 2012-07-12 US disclosed
US-8168649-B2 Niacin receptor agonists, compositions containing such compounds and methods of treatment Merk Sharp & Dohme Corp. (US) 2012-05-01 US disclosed
US-8168649-B2 Niacin receptor agonists, compositions containing such compounds and methods of treatment Merk Sharp & Dohme Corp. (US) 2012-05-01 US disclosed
US-20100144778-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME LLC 2010-06-10 US disclosed
US-20100144778-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME LLC 2010-06-10 US disclosed
WO-2007002557-A1 NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK & CO., INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144778-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment HCAR1, HCAR2, GPR119 SMN1; SMN2 4003/4885MMP8 2178/4885ALDH1A1 1145/4885
US-20120178750-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment HCAR1, HCAR2, FFAR1 SMN1; SMN2 3840/4885MMP8 2113/4885ALDH1A1 1106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.